Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Test for sepsis therapy proves its worth:

This article was originally published in Clinica

Executive Summary

A dry chemistry test developed by Cardiovascular Diagnostics has proved its viability in evaluating the effect of Eli Lilly's therapeutic anticoagulant on patients with sepsis. The next step will be to carry out further testing of patient samples in order to define the test parameters. As a result, Cardiovascular Diagnostics expects to alter the formulation of the test. Sepsis has a mortality rate of 30-50% and is caused by pathogens circulating in the blood which results in serious complications such as organ failure.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT086466

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel